CROI 2023 – GSK and Gilead’s long-acting HIV battle intensifies

GSK has long been the trailblazer in long-acting HIV therapies, and at last week’s Conference on Retroviruses and Opportunistic Infections (CROI) the group touted data with its doublet Cabenuva, which can be given as infrequently as every two months.